Valuation: Collegium Pharmaceutical, Inc.

Market Cap 90Cr 77Cr 72Cr 66Cr 123.49Cr 8.58TCr 125.92Cr 849.68Cr 331.22Cr 4.3TCr 336.65Cr 329.32Cr 14TCr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 90Cr 77Cr 72Cr 66Cr 123.49Cr 8.58TCr 125.92Cr 849.68Cr 331.22Cr 4.3TCr 336.65Cr 329.32Cr 14TCr EV / Sales 2026 *
1.07x
EV / Sales 2027 * 1.08x
Free-Float
77.39%
Yield 2026 *
-
Yield 2027 * -
1 week-3.28%
Current month-22.88%
1 month-23.87%
3 months-19.74%
6 months-38.52%
Current year-43.81%
1 week 23.6
Extreme 23.6
25
1 month 22.2
Extreme 22.2
32
3 years 20
Extreme 20
42.4
Manager TitleAgeSince
Chief Executive Officer 51 12/11/2024
Director of Finance/CFO 50 24/05/2021
Chief Tech/Sci/R&D Officer 65 23/03/2022
Director TitleAgeSince
Chairman 69 15/05/2025
Director/Board Member 72 01/02/2014
Director/Board Member 78 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.28%-28.05%+8.26% 90Cr
-2.81%+2.93%+76.40%+127.73% 1,10900Cr
-2.21%+2.02%+49.50%+55.01% 64TCr
-1.56%+4.39%+25.19%+74.39% 46TCr
-1.34%+2.62%+41.69%+45.78% 37TCr
-0.93%+2.10%+23.43%+41.34% 30TCr
-0.69%+3.25%+0.94%+13.42% 26TCr
-1.95%+3.80%+46.31%+65.66% 23TCr
+0.57%-0.70%-14.31%-52.66% 20TCr
-2.82%+3.84%+20.81%+89.04% 18TCr
Average -1.56%+3.00%+24.19%+46.79% 41.79TCr
Weighted average by Cap. -1.90%+3.26%+43.24%+70.40%

Financials

2026 *2027 *
Net sales 84Cr 72Cr 67Cr 61Cr 115.26Cr 8.01TCr 117.53Cr 793.03Cr 309.14Cr 4.01TCr 314.2Cr 307.36Cr 13TCr 83Cr 71Cr 66Cr 61Cr 114.06Cr 7.92TCr 116.31Cr 784.78Cr 305.92Cr 3.97TCr 310.93Cr 304.17Cr 13TCr
Net income - -
Net Debt - -
Logo Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.
Employees
-
Date Price Change
21/26/21 23.60 0.00%
20/26/20 €23.60 -4.84%
19/26/19 €24.80 +0.81%
18/26/18 €24.60 0.00%
17/26/17 €24.60 +1.65%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
27.54USD
Average target price
49.60USD
Spread / Average Target
+80.10%

Quarterly revenue - Rate of surprise